OncoMatch/Clinical Trials/NCT05826535
Study of LYL314 in Aggressive Large B-Cell Lymphoma
Is NCT05826535 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including LYL314 and Fludarabine for relapsed non-hodgkin lymphoma.
Treatment: LYL314 · Fludarabine · Cyclophosphamide — This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 monoclonal antibody
Prior therapy must have included: Anti-CD20 monoclonal antibody
Must have received: anthracycline
Prior therapy must have included: An anthracycline containing chemotherapy regimen
Cannot have received: allogeneic stem cell transplantation
History of allogeneic stem cell or solid organ transplantation
Cannot have received: autologous stem cell transplantation
Exception: within 6 weeks prior to enrollment/leukapheresis
Receipt of autologous stem cell transplantation within 6 weeks prior to enrollment/leukapheresis
Cannot have received: genetically modified cell therapy
Exception: CD19 with an FMC63-based CAR (e.g., axi-cel, tisa-cel, liso-cel) allowed
History of prior genetically modified cell therapy other than a product targeting CD19 with an FMC63-based CAR (e.g., axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), or lisocabtagene maraleucel (liso-cel). For all other CAR T cell therapy treatments, discussion with the Sponsor's Medical Monitor is required
Lab requirements
Blood counts
ANC ≥ 1000/uL; Platelet count ≥ 50,000/uL; Absolute lymphocyte count (ALC) ≥ 200/uL
Absolute neutrophil count (ANC) ≥ 1000/uL; Platelet count ≥ 50,000/uL; Absolute lymphocyte count (ALC) ≥ 200/uL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California-Irvine Medical Center · Irvine, California
- Cedars-Sinai Medical Center · Los Angeles, California
- University of California, Los Angeles (UCLA) Medical Center · Los Angeles, California
- Scripps Clinic · San Diego, California
- Colorado Blood Cancer Institute · Denver, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify